Pharminent

Teva, Celltrion Announce Exclusive Biosimilar Commercial Partnership

NewsBoth CT-P10 and CT-P6 are currently in late-stage Phase III development and their primary endpoints have been successfully achieved.Topics: Life Sciences http://www.dddmag.com/news/2016/10/teva-celltrion-announce-exclusive-biosimilar-commercial-partnership

Filed under: Biosimilar